South Koreans cross into Japan to buy cheaper Mounjaro, exposing price arbitrage and supply‑chain pressure for the obesity drug
Executive summary: South Koreans are buying Mounjaro in Japan and transporting it to South Korea for off‑label weight‑loss purposes. The practice reveals price gaps between the two markets, risks drug diversion and unsupervised use, and may trigger regulatory scrutiny from both countries’ health authorities.
Who is involved: South Korean consumers, Japanese pharmacies/retailers, Eli Lilly (the maker of Mounjaro), South Korean Ministry of Food and Drug Safety and Japan’s Ministry of Health, Labour and Welfare.
Likely next (inference): Authorities may increase border checks, consider price adjustments or export restrictions, and Eli Lilly could review its Asia‑Pacific pricing strategy.
The Nikkei Asia report describes South Korean travelers purchasing Mounjaro (tirzepatide) in Japan, where the drug is sold at a lower price, and bringing it back for personal weight‑loss use. This cross‑border behavior highlights disparities in national pricing and reimbursement policies for emerging obesity therapeutics. While the article does not quantify the volume of such trips, it points to a growing informal market that could undermine manufacturers’ pricing strategies and raise safety concerns about unsupervised drug use.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Base: Japan tightens export controls (40%)
Fewer South Korean travelers can obtain the drug abroad, pushing demand toward domestic channels or alternative therapies.
- Japan’s MHLW announces revised export quota for Mounjaro (observed within the next 4‑6 weeks)
- Customs data shows a decline in outbound Mounjaro shipments to South Korea
Upside: Korea approves price subsidy/faster reimbursement (30%)
Domestic sales rise, reducing smuggling and stabilizing Eli Lilly’s Asia‑Pacific revenue.
- South Korean MFDS issues a positive pricing decision for Mounjaro (expected by Q1 2027)
- Health insurance adds Mounjaro to reimbursement list
Downside: Smuggling expands, causing shortages and stricter penalties (30%)
Japanese pharmacies report stockouts; both countries increase fines and criminal charges for illegal drug import/export.
- Japanese pharmacies report Mounjaro stockouts in major cities (reported in news within the next 2 months)
- South Korean customs announces heightened penalties for prescription drug smuggling (effective Q4 2026)
What to watch
- Japanese MHLW announcement on export licensing for Mounjaro (expected within 4‑6 weeks)
- South Korean MFDS pricing decision for Mounjaro (anticipated Q1 2027)
- Customs seizure volumes of Mounjaro at Incheon International Airport (monthly reports)
- Eli Lilly’s Asia‑Pacific sales guidance update in next quarterly earnings call
- Japanese pharmacy association reports on Mounjaro inventory levels (monthly surveys)
Timeline
- — South Koreans are sneaking cheap Mounjaro home from Japan to lose weight (Nikkei Asia)